Sort
82,697 grants matching “vaccine development”
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2022 · AI
Diabetes Evaluation in Washington (DEW-IT) Clinical Cen*
$1,000,000Pacific Northwest Research Institute · U01 · FY2003 · DK
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
$1,000,000Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2022 · CA
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
Experimental Gonococcal Vaccine
$1,000,000Dominick Auci · Therapyx, Inc. · R44 · FY2021 · AI
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2013 · AI
Therapeutic Antibody for RSV IIB
$1,000,000Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2019 · AI
Pre-IND Development of an Arenavirus Antiviral
$1,000,000Gregory William Henkel · Arisan Therapeutics, Inc. · R44 · FY2020 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · AI
Advancement of antiviral inhibitors of chikungunya virus
$1,000,000Daniel C Pevear · Venatorx Pharmaceuticals, Inc. · R44 · FY2019 · AI
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
$1,000,000Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2017 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN INFLUENZA VIRUSES (AIV) ARE ENDEMIC IN CERTAIN WILD BIRD POPULATIONS, AND FROM THERE, SPILL OVER INTO DOMESTIC BIRDS AND HUMAN POPULATIONS WHERE THEY CAUSE OUTBREAKS OF SEVERE DISEASE. SOME STRAINS OF AIV POSE A GREATER THREAT THAN OTHERS, BECAUSE OF A COMBINATION OF THEIR PATHOGENICITY, GEOGRAPHIC AND HOST RANGE; EXEMPLIFIED IN RECENT YEARS BY FOUR MAJOR INCURSIONS OF H5 AND H7 SUBTYPE VIRUSES. SURVEILLANCE BACKED UP BY LABORATORY ASSESSMENT OF THESE TRAITS UNDERPIN ATTEMPTS TO RISK ASSESS AND PREDICT BEHAVIOUR OF A HIGHLY MUTABLE VIRUS. THIS SURVEILLANCE EFFORT, COUPLED WITH THE DEVELOPMENT OF SEQUENCING TECHNOLOGY HAS LED TO AN EXPONENTIAL RISE INTHE AMOUNT OF VIRAL SEQUENCE DATA, BOTH AT CONSENSUS LEVEL AND (VIA NEXT GENERATION SEQUENCING [NGS]) AT QUASI-SPECIES LEVEL. IN PARALLEL, RECENT ADVANCES IN PHYLODYNAMIC MODELLING TECHNIQUES (INCLUDING STRUCTURED COALESCENTS, MULTI-SPECIES BIRTH-DEATH MODELS AND INTEGRATION OF TIME-DEPENDENT PREDICTORS IN GENERALISED LINEAR MODEL PHYLOGEOGRAPHIC APPROACHES HAVE PROVIDED METHODS TO FULLY USE THIS WEALTH OF DATA. ACCORDINGLY, WE HYPOTHESISE THAT, FOR THE FIRST TIME, PROPERLY PARAMETERISED MATHEMATICAL MODELS OF VIRAL EVOLUTION WITH GENUINEPREDICTIVE VALUE CAN NOW BE CONSTRUCTED. WE WILL GENERATE THESE MODELS AND PRODUCE SPREAD AND HOST RANGE RISK MAPS FOR SPECIFIC AIV STRAINS THAT CAN BE USED TO INFORM VACCINATION AND OTHER CONTROL STRATEGIES.
$1,000,000Agricultural Research Service · · FY2021 · National Institute of Food and Agriculture
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$1,000,000Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2022 · AI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry
$1,000,000Brett D Welch · Navigen, Inc. · R44 · FY2015 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2015 · AI
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2010 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2021 · AI
Environmental Causes of Type 1 Diabetes
$1,000,000University Of Colorado Denver · U01 · FY2003 · DK
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
$1,000,000Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2019 · AI
HIV pathogenesis, prevention and treatment in the Andes
$1,000,000Asociacion Civil Impacta Salud Y Educacn · U19 · FY2004 · AI
Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
$1,000,000Peter F. Billingsley · Sanaria, Inc. · R44 · FY2013 · AI
Recombinant Subunit Vaccine For Tick-Borne Encephalitis
$1,000,000Beth-Ann Coller · Hawaii Biotech, Inc. · R44 · FY2010 · AI
Delivery system development for a reservoir targeted Lyme disease vaccine
$1,000,000Linden T Hu · Foodsource Lure Corporation · R42 · FY2013 · AI
SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies
$1,000,000Mohammad Noshi · Akanocure Pharmaceuticals, Inc. · · FY2024 · TIP